This site is intended for US Healthcare Professionals.
This medical information is intended only for healthcare professionals registered to practice in the United States and is intended to provide balanced, scientific, and evidence-based answers to unsolicited medical questions. Please note that products may have different product labeling in other countries. The information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience, and knowledge of the individual patient. This resource may include information that has not been approved by the US Food and Drug Administration. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling.
Explore Clinical Studies, and Research for Key Products
This information is intended for healthcare professionals only. Display of investigational compounds does not imply regulatory approval for these compounds or indications. Information on approved medicines does not suggest use in a manner inconsistent with approved labeling. Information about all GSK-sponsored trials can be found at www.clinicaltrials.gov
Trademarks are owned by or licensed to the GSK group of companies. ©2020 GSK or licensor. May 2020. Produced in USA
To report suspected adverse reactions, please call us at 1-888-825-5249, or call the FDA at 1-800-FDA-1088 You may also report suspected adverse reactions to the FDA at www.fda.gov/medwatch.
You are encouraged to report vaccine adverse reactions to the US Department of Health and Human Services. Visit www.vaers.hhs.gov to file a report, or call 1-800-822-7967.
First Lastname
Title
First Lastname
Title
First Lastname
Title
First Lastname
Title
First Lastname
Title
First Lastname
Title
December 1-4, 2018
March 16-19, 2019
For a copy of a poster please call 1-877-475-6448
June 11-21, 2020 | Virtual
Dec 10–14, 2019 | San Antonio, Texas
Pilot Neoadjuvant Study of Niraparib in HER2-Negative, BRCA-Mutated Resectable Breast Cancer
September 9-12, 2020 | Virtual Meeting
September 9-12, 2020 | Virtual Meeting
1. Symposium: The Evolving Therapeutic Landscape in Relapsed/Refractory Multiple Myeloma
April 2020 | Virtual
April 2020 | Virtual
Apr 29-May 3, 2020 | Virtual
December 14-16, 2020 | Virtual Meeting
December 14-16, 2020 | Virtual Meeting
4. Systematic Literature Review of Efficacy and Safety of First-Line Maintenance Therapy Trials
Apr 27, 2020 | Virtual Annual Meeting I
Mar 13-16, 2020 | Philadelphia, PA (Cancelled due to COVID-19)
Eosinophilic Granulomatosis with Polyangiitis (EGPA): Pathogenesis, Diagnosis, and Management
The Role of Eosinophilic and Their Potential Heterogeneity in Airways Disease
May 29-June 2, 2020 | Virtual Meeting
May 29-June 2, 2020 | Virtual Meeting
3. Evaluation of an Individualized Starting Dose of Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Study
8. Plain Language Summary [HCP USE ONLY]: The DREAMM-2 Study: What Were the Effects of Belantamab Mafodotin in Patients With Multiple Myeloma and DNA Patterns That Are Considered ‘High-Risk’?
Publication Only: Real-World Treatment Patterns of Maintenance therapy in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: Are Some Patients Missing Out?
Publication Only: Treatment Patterns of Advanced or Recurrent Endometrial Cancer Following Platinum-Based Therapy in the US Real-World Setting
Publication Only: Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab
Publication Only: DREAMM-1: Patient Perspectives from the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed and Refractory Multiple Myeloma (RRMM)
Publication Only: DREAMM-2: Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed Relapsed/Refractory Multiple Myeloma
Publication Only: Current Treatment Efficacy for Metastatic Soft Tissue Sarcoma: A Targeted Literature Review
Publication Only: Qualitative Patient Interviews on Symptoms and Impacts in Metastatic Synovial Sarcoma (mSS)
Publication Only: Epidemiology of Adenoid Cystic Carcinoma in the United States
January 15-17, 2021 | Virtual Meeting
Belantamab mafodotin:
Dostarlimab
ICOS Agonist IgG4 Antibody
TIM-3 Antagonist Antibody (Cobolimab)
LAG-3 Antagonist Antibody (TSR-033)
STING Agonist (GSK3745417)
Bintrafusp Alfa Bifunctional TGF-β “Trap”/Anti-PD-L1 Fusion Protein
OX40 Agonist Antibody (GSK3174998)
Belantamab Mafodotin - Anti-BCMA Immunoconjugate
NY-ESO-ImmTAC (IMCnyeso)
Anti-CD96 Antibody (GSK6097608)
Molibresib BET Inhibitor
PRMT5 Inhibitor (GSK3326595) and Type I PRMT Inhibitor (GSK3368715)
PI3Kβ Inhibitor (GSK2636771)
Niraparib (PARP Inhibitor)
October, 2018
June, 2019
June, 2019
1. Chaudhuri R, Canonica GW, Bals R, et al. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. [Poster No. 714; Abstract A4267].
2. Hahn B, Bogart M, Silver J, et al. Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. [Poster No. 804; Abstract A7741].
3. Molfino NA, Averell CM, Hahn BA, et al. Patients with Uncontrolled Asthma Eligible for a Biologic. [Poster No. 801; Abstract A7738].
4. Moore WC, Kornmann O, Humbert M, et al. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. [Oral presentation available here; Abstract A4211].
5. Moraes F, Abreu G, Nogueira T, et al. Characterization of severe asthma patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. [Poster No. 712; Abstract A1827].
6. Moraes F, Abreu G, Nogueira T, et al. Prevalence of asthma and severe asthma in patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. [Poster No. 710; Abstract A1825].
7. Verhamme K, de Ridder M, Webb D, et al. Differences in Patient Characteristics between Asthma Patients with and without Eosinophil Measurements. [Poster No. P792; Abstract A5630].
8. Wu AC, McMahon PM, Mendelsohn A, et al. Use of Mepolizumab among Individuals with Asthma in the U.S. [Poster No. P742; Abstract A4771].
1. Prazma C, Bernstein D, Brightling C, et al. The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. [Poster No. 1301; Abstract A1312].
1. Bell CF, Blauer-Peterson C. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. [Poster No. P1286; Abstract A6579].
1. Steinfeld J, Roufosse F, Kahn JE, et al. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. [Oral presentation available here; Abstract A4212].
1. Averell CM, Hahn BA, Zografos L, et al. Assessment of Asthma Control in Respiratory Specialist Offices in the US. [Poster No. P711; Abstract A1826].
2. Bogart M, Chastek B, White J, et al. Treatment Patterns and Disease Burden of Triple Therapy in Asthma. [Poster No. P805; Abstract A7742].
3. Davitte J, DeBarmore B, Hinds D, et al. Asthma control among the treated U.S. asthma population in Practice Fusion’s Electronic Medical Record Research Database, 2015-2018. [Poster No. P699; Abstract A1814].
4. Fowler A, Kerstjens HAM, Bailes Z, et al. CAPTAIN Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship With Trough FEV1. [Poster No. P788; Abstract A5626].
5. Kerstjens HA, Pavord ID, Peachey G, et al. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. [Oral presentation available here; Abstract A4209].
6. Lee LA, Boulet LP, Fowler A, et al. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. [Poster No. P787; Abstract A5625].
7. Molfino NA, Averell CM, Hahn BA, et al. Real World Evidence in Asthma: Pulmonary Function and Asthma Control in Respiratory Specialty Clinics in the US. [Poster No. P372; Abstract A6482]
8. Pavord ID, Fowler A, Kerstjens HA, et al. CAPTAIN Study: Treatable Traits and the Outcome of Treatment with Inhaled Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI Therapies in Patients with Uncontrolled Asthma, a Pre-specified Subgroup Analysis. [Oral presentation available here; Abstract A6247].
9. Sansbury LB, Hinds D, Chao J, et al. Treatment sequencing among asthma patients who were newly treated with long-acting antimuscarinic antagonist (LAMA) in the United States. [Poster No. P713; Abstract A1828]
10. Tabberer M, von Maltzahn R, Bacci E, et al. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS®: Asthma in Two Clinical Trials of Moderate to Severe Asthma. [Poster No. P786; Abstract A5624]
1. Anderson M, Drummond MB, Jain R, et al. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. [Poster No. P813; Abstract A4302].
2. Ferguson GT, Brown N, Compton C, et al. Once-Daily Single-Inhaler Versus Twice-Daily Multiple-Inhaler Triple Therapy: Two Replicate Trials in Patients With Chronic Obstructive Pulmonary Disease (COPD). [Poster No. P806; Abstract A4295].
3. Halpin DMG, Worsley S, Ismaila AS, et al. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. [Poster No. P824; Abstract A4313].
4. Mularski R, Wu B, Fuoco MJ, et al. Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations. [Poster No. P276; Abstract A4811].
5. Mularski RA, Drummond MB, Jain R, et al. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. [Poster No. P1045; Abstract A5050].
6. Obeid D, Bansal S, Brown N, et al. Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations. [Poster No. 805; Abstract A4294].
7. Bjermer L, Maltais F, Vogelmeier CF, et al. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. [Poster No. P1091; Abstract A3326].
8. Cole AL, Moretz C, Mu G, et al. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database. [Poster No. 817; Abstract A4306].
9. Kerwin EM, Maltais F, Boucot IH, et al. Analysis of a Composite Endpoint of Exacerbation and Early Study Treatment Withdrawal in Symptomatic Patients With COPD Free of Inhaled Corticosteroids: A Post Hoc Analysis of the EMAX Trial. [Poster No. 518; Abstract A4579].
10. Kerwin EM, Bjermer L, Maltais F, et al. Rescue Medication Use as an Indicator of Symptom Burden in Patients With COPD: A Post Hoc Analysis of the EMAX Trial. [Poster No. 1089; Abstract A3324].
11. Moretz C, Hahn B, White J, et al. Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. [Poster No. 811; Abstract A4300].
12. Vogelmeier CF, Kerwin EM, Naya IP, et al. Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. [Poster No. 1053; Abstract A5058].
13. Vogelmeier CF, Boucot IH, Kerwin EM, et al. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. [Poster No. 1090; Abstract A3325].
14. Keir HR, Richardson H, Mayhew D, et al. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. [Poster No. P474; Abstract A3997].
1. Exacerbation Reduction in Patients Based Upon Baseline Eosinophil Counts and FEV1 Reversibility
4. Practical Use of ELLIPTA, a Once-Daily, Dry Powder Inhaler for Children With Asthma
5. Nasal Polyp Symptoms: How Well Do Physicians Know Their Patients?
8. Efficacy of Mepolizumab Stratified by Baseline Blood Eosinophil Count
1. Chapman KR, Devouassoux G, Liu MC, et al. Switch from omalizumab to mepolizumab in severe eosinophilic asthma: effect of weight and BMI. [Poster No. P205; Abstract 8039].
2. Liu M, Bel E, Kornmann O, et al. Clinician/Patient Perception: Asthma Severity Decreases and Response Increases With Continuing Versus Stopping Long-term Mepolizumab (COMET). [Poster No. P211; Abstract 8056].
1. Averell CM, Germain G , Laliberté F, et al. HO-19-19563 - Asthma-Related Exacerbations and SABA Use Associated With Once-Daily Fluticasone Furoate/Vilanterol Compared To Twice-Daily Budesonide/Formoterol. [Poster No. P218; Abstract 8091].
2. Averell CM, Laliberté F, Germain G, et al. HO-18-18648 - Disease Burden And Treatment Adherence Among Children And Adolescent Patients With Asthma. [Poster No. P217; Abstract 8079].
3. Hanania N, Bailes Z, Barnes N, et al. CAPTAIN Study: Effects of Fluticasone Furoate/Umeclidinium/Vilanterol on FEV1 Improvement in Asthma According to Age. [Poster No. P206; Abstract 8041].
4. Oppenheimer J, Brusselle G, Busse W, et al. CAPTAIN Study: Treatment Outcomes from Fluticasone Furoate/Umeclidinium/Vilanterol According to History of Severe Asthma Exacerbations. [Poster No. P202; Abstract 8031].
1. Irani A-M, Prazma C, Bajaj B, et al. Successful Liver Transplantation in a Patient with Hypereosinophilic Syndrome treated with Mepolizumab. [Poster No. M239; Abstract 9050].
1. Bachert C, Sousa A, Han J, et al. Mepolizumab for Chronic Rhinosinusitis With Nasal Polyps: Comorbid Asthma, NSAID Exacerbated Respiratory Disease, Eosinophil Stratification. [Poster No. P503; Abstract 8052].
1. Silver J, Bogart M, Molfino N, et al. Reasons why patients with severe asthma discontinue biologic treatment. Poster No. P0018.
2. Silver J, Bogart M, Molfino N, et al. Impact of mepolizumab in patients with life-threatening asthma. Poster No. P0017.
1. Nathan R, Boulet L-P, Kerstjens HA, et al. CAPTAIN Study: Effect of baseline lung function on response to triple therapy in patients with asthma inadequately controlled on inhaled corticosteroid/long-acting β2-agonist therapy. Poster No. P1483.
2. Ramesh N, Hegewald M, Maselli DJ, et al. Views of US pulmonologists on the prevalence of uncontrolled asthma, treatment decisions and the role of treatable traits: results from the CHEST Pulse Surveys. Poster No. P1488.
3. Sule N, Fowler A, Kerstjens HA, et al. CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial. Oral presentation.
4. Zhang S, White J, Meeraus W, et al. Prevalence of asthma control and the associated disease burden in US patients with asthma treated with a fixed-dose combination of inhaled corticosteroid and long-acting β2-agonist. Poster No. P1512.
1. Anzueto A, Obeid D, Bansal S, et al. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol compared with tiotropium monotherapy in chronic obstructive pulmonary disease: a post hoc analysis by airflow limitation. Poster No. P1440.
2. Bogart M, Wu B, Germain G, et al. Real-world adherence to single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in a commercially insured US population. Poster No. P1444.
3. Calverley PMA, Celli BR, Crim C, et al. Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate-containing therapy: Post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation. Poster No. P1448.
4. Criner GJ, Barnes N, Brusselle G, et al. Demographic and clinical characteristics of patients experiencing on-treatment exacerbations, on-treatment death or premature study treatment withdrawal: The IMPACT Trial. Poster No. P1454.
5. Dransfield MT, Halpin DMG, Han MK, et al. Time-dependent risk of cardiovascular events following an exacerbation in patients with COPD: post hoc analysis from the IMPACT trial. Poster No. P1458.
6. Han MK, Bratton DJ, Hartley B, et al. Benefit–risk profiles of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease: a Markov model. Oral presentation.
7. Hosking L, Yeo A, Hoffman J, et al. Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and its components. Poster No. P1501.
8. Mannino D, Siddall J, Small M, et al. Cross-sectional survey to assess chronic obstructive pulmonary disease (COPD) medication use by United States (US) physicians. Poster No. P1446.
9. Soler X, Siddall J, Small M, et al. Cross-sectional survey to assess the burden of nocturnal symptoms in patients with chronic obstructive pulmonary disease (COPD). Poster No. P1445.
10. Slade D, Ray R, Moretz C, et al. Medication adherence and COPD-related costs among patients with COPD treated with umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO). Poster No. 1467.
11. Slade D, Ray R, Moretz C, et al. Umeclidinium/vilanterol (UMEC/VI) compared with tiotropium (TIO) for time-to-first inpatient admission among patients with chronic obstructive pulmonary disease in a managed care population. Poster No. 1465.
12. Slade D, Ray R, Moretz C, et al. Impact of umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), fluticasone propionate/salmeterol (FP/SAL), and budesonide/formoterol (B/F) on time-to-first severe exacerbation among patients with chronic obstructive pulmonary disease with high comorbidities and high costs. Poster No. 1466.
13. McCreary G, Yawn BP, Linnell J, et al. Assessment of patient interaction with a dry powder inhaler electronic medication monitor and integrated system within the Chronic Obstructive Pulmonary Disease Foundation Patient Powered Research Network. Poster No. P1481.
14. Thompson-Leduc P, Ghaswalla P, Cheng WY, et al. Chronic obstructive pulmonary disease is associated with an increased risk of herpes zoster: a retrospective analysis of a United States claims database from 2013-2018. Poster No. P1505.
Mar 13-16, 2020
Mar 13-16, 2020
1. Exacerbation Reduction in Patients Based Upon Baseline Eosinophil Counts and FEV1 Reversibility
4. Practical Use of ELLIPTA, a Once-Daily, Dry Powder Inhaler for Children With Asthma
5. Nasal Polyp Symptoms: How Well Do Physicians Know Their Patients?
8. Efficacy of Mepolizumab Stratified by Baseline Blood Eosinophil Count
Oct 21-25, 2020
1. #Vaccine Twitter Influencers: Is it Just About Reach and Followers?
5. Assessment of Recombinant Zoster Vaccine Second-Dose Completion in the United States
6. Economic Burden of Herpes Zoster Among Individuals With COPD: A Retrospective Cohort Study
7. The Potential for Reducing Opioid and Analgesic Prescriptions via Herpes Zoster Vaccination
Apr 27, 2020 | Virtual Annual Meeting I
December 5-8, 2020 | Virtual Meeting
10. Population-level Projections for Multiple Myeloma Patients by Line of Therapy in the USA
Publication Only: Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data From the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)
Publication Only: Real-world Incidence and Clinical and Economic Burden of Managing Ocular Events (OE) in Patients with Active Multiple Myeloma (MM)
November 9-14, 2020 | Virtual Meeting
September 19-21, 2020 | Virtual Meeting
September 19-21, 2020 | Virtual Meeting
November 16-19, 2020 | Virtual Meeting
NY-ESO-1 TCR T Cell (GSK3377794)
February 27-29, 2020 | Scottsdale, AZ
October 3-4, 2020 | Virtual Meeting
January 23-25, 2020 | San Francisco, CA
October 22-25, 2020 | Virtual
2. Burden of Illness of Lupus Nephritis in Patients With Systemic Lupus Erythematosus
November 5-9, 2020 | Virtual
From June 3, 2020 | Virtual
October 22-25, 2020 | Virtual
May 18-20, 2020 | Virtual Meeting
September 19-21, 2020 | Virtual Meeting
1. Treatment Options for Women with Advanced Ovarian Cancer: Evaluating the Evidence